

Effectiveness and safety of ICS-LABA* delivered through synchrObreathe™ in patients with asthma: the real-world EVOLVE study

OBJECTIVE

Evaluate asthma control and device usability with ICS-LABA



STUDY DESIGN

The present study was a prospective, open-label, non-comparative, multi-center, observational study

NUMBER OF PATIENTS

n=490

RESULTS



ICS: Inhaled corticosteroids | LABA: Long-Acting Beta Agonists | ACQ - Asthma Control Questionnaire
*Salmeterol/fluticasone Fixed Dose Combination | 1. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221137272